141 related articles for article (PubMed ID: 6131495)
1. Drug-induced growth hormone and prolactin responses in schizophrenia research.
Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
[TBL] [Abstract][Full Text] [Related]
2. Effect of naloxone or levallorphan on serum prolactin concentrations and apomorphine-induced growth hormone secretion.
Lal S; Nair NP; Cervantes P; Pulman J; Guyda H
Acta Psychiatr Scand; 1979 Feb; 59(2):173-9. PubMed ID: 420037
[TBL] [Abstract][Full Text] [Related]
3. Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.
Nair NP; Lal S; Cervantes P; Yassa R; Guyda H
Neuropsychobiology; 1979; 5(3):136-42. PubMed ID: 431802
[TBL] [Abstract][Full Text] [Related]
4. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
[TBL] [Abstract][Full Text] [Related]
5. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
Kolakowska T; Gelder M; Fraser S
Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
[TBL] [Abstract][Full Text] [Related]
8. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
9. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis.
Smith S; Wheeler MJ; Murray R; O'Keane V
J Clin Psychopharmacol; 2002 Apr; 22(2):109-14. PubMed ID: 11910254
[TBL] [Abstract][Full Text] [Related]
10. A neuroendocrine study of supersensitivity in tardive dyskinesia.
Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
[TBL] [Abstract][Full Text] [Related]
11. Effects of dopamine agonists in tardive dyskinesia.
Smith RC; Tamminga CA; Haraszti J; Pandey GN; Davis JM
Am J Psychiatry; 1977 Jul; 134(7):763-8. PubMed ID: 869053
[TBL] [Abstract][Full Text] [Related]
12. Hormones, dopamine receptors and schizophrenia.
Meltzer HY; Busch D; Fang VS
Psychoneuroendocrinology; 1981; 6(1):17-36. PubMed ID: 7244055
[No Abstract] [Full Text] [Related]
13. [Neuroendocrinology and schizophrenia research].
Müller-Spahn F
Monogr Gesamtgeb Psychiatr Psychiatry Ser; 1991; 64():1-96. PubMed ID: 1682802
[No Abstract] [Full Text] [Related]
14. An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels.
Mielke DH; Gallant DM; Kessler C
Am J Psychiatry; 1977 Dec; 134(12):1371-5. PubMed ID: 21571
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication.
Cotes PM; Crow TJ; Johnstone EC; Bartlett W; Bourne RC
Psychol Med; 1978 Nov; 8(4):657-65. PubMed ID: 364517
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte monoamine oxidase and plasma prolactin and growth hormone in tardive dyskinesia.
Jeste DV; Neckers LM; Wagner RL; Wise CD; Staub RA; Rogol A; Potkin SG; Bridge TP; Wyatt RJ
J Clin Psychiatry; 1981 Feb; 42(2):75-7. PubMed ID: 6109719
[TBL] [Abstract][Full Text] [Related]
18. Hormonal effects of apomorphine in schizophrenia.
Ferrier IN; Johnstone EC; Crow TJ
Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
[TBL] [Abstract][Full Text] [Related]
19. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
Meltzer HY; Lee MA; Jayathilake K
Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
[TBL] [Abstract][Full Text] [Related]
20. Effect of lithium on hypothalamic-pituitary dopaminergic function.
Lal S; Nair NP; Guyda H
Acta Psychiatr Scand; 1978 Jan; 57(1):91-6. PubMed ID: 636903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
